Evidence map›Paper›PMID 33467652›Full record

ArticlePharmaceutics2021

Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes.

Debra Wu, Douglas Vogus, Vinu Krishnan, Marta Broto, Anusha Pusuluri, Zongmin Zhao, Neha Kapate, Samir Mitragotri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. The Promise of Nanotechnology in Personalized Medicine.Journal of personalized medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Debra WuJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Douglas VogusJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Vinu KrishnanJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Marta BrotoDepartment of Materials, Department of Bioengineering and Institute of Biomedical Engineering, Imperial College London, South Kensington, London SW7 2BU, UK.
Anusha PusuluriJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Zongmin ZhaoJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-8979-844X
Neha KapateJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-4576-0014
Samir MitragotriJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.

Funding

Harvard University Funding from Harvard U and Promius Pharma (see acknowledgements)
6 · The paper itself

Abstract

Liposome-based drug delivery systems have allowed for better drug tolerability and longer circulation times but are often optimized for a single agent due to the inherent difficulty of co-encapsulating two drugs with differing chemical profiles. Here, we design and test a prodrug based on a ribosylated nucleoside form of 5-fluorouracil, 5-fluorouridine (5FUR), with the final purpose of co-encapsulation with doxorubicin (DOX) in liposomes. To improve the loading of 5FUR, we developed two 5FUR prodrugs that involved the conjugation of either one or three moieties of tryptophan (W) known respectively as, 5FUR-W and 5FUR-W

Indexed as

drug combinationliposomenanoparticletargeting

Identifiers

PMID33467652
PMCPMC7830726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.